Experience

Universidad Francisco de Vitoria

• Spain
• Higher Education
• 700 & Above Employee

• Profesora Tiempo parcial Universidad Francisco de Vitoria

  • Jan 2022 - Present

  Profesora a tiempo parcial de en la carrera de Ingeniería Biomedica Profesora a tiempo parcial de en la carrera de Ingeniería Biomedica



ARQUIMEA Healthcare

• Spain
• Wellness and Fitness Services
• 1 - 100 Employee

• General Manager

  • Mar 2020 - Present

  Arquimea Medical, part of ARQUIMEA Group, is a healthcare company, focused in the research, development and marketing of new devices and diagnostic products to improve population health and quality of life. In this regard, we are leading a net of laboratories in Spain to detect Covid 19 though PCR and ELISA testing. Our goal is to bring early diagnosis to the population with a competitive price, high quality and fast results. Arquimea Medical, part of ARQUIMEA Group, is a healthcare company, focused in the research, development and marketing of new devices and diagnostic products to improve population health and quality of life. In this regard, we are leading a net of laboratories in Spain to detect Covid 19 though PCR and ELISA testing. Our goal is to bring early diagnosis to the population with a competitive price, high quality and fast results.



4basebio

• Consejera y presidente comite remuneraciones

  • Jan 2020 - Present



ADL BioPharma

• Spain
• Pharmaceutical Manufacturing
• 100 - 200 Employee

• CEO

  • Jul 2017 - Jan 2020



BIAT GROUP

• Biotechnology Research
• 1 - 100 Employee

• CEO/Consejero delegado

  • Jul 2017 - Jan 2020



SYGNIS

• Biotechnology
• 1 - 100 Employee

• CEO

  • Dec 2012 - Jul 2017

  Frankfurt stock Exchange listed company, which main focus is to develop and license out DNA tools for amplification and sequencing since December 2012. At that time, the company merged with XPol, a subsidiary of Genetrix group. After the merger, the new entity changes the main focus of the company to develop DNA tools, and closed all the activities linked to drug discovery and drug development. I was nominated as CEO of the new entity and, in March 2013, I was also nominated to cover the CFO position. The company has two facilities, one in Madrid Spain, and another one in Heidelberg, Germany. During this time she has closed successfully 3 capital increases, last one closed in December 2015, and has moved successfully the company to the DNA reagent market, launching a complete portfolio of new tools targeting NGS users. The company is now growing and focusing in expanding the comercial activities.



Genetrix

• Spain
• Biotechnology Research
• 1 - 100 Employee

• Consejero Delegado (CEO)

  • Dec 2010 - Dec 2012

  During this period she was in charge of restructuring and optimizing the holding , closing the projects and business wth low probabilities of high returns, and focusing the resources in the projects with high potential. In this sense, she leaded the merger between XPol and Sygnis AG as a reverse acquisition aiming to be public in the German market. During this period she was in charge of restructuring and optimizing the holding , closing the projects and business wth low probabilities of high returns, and focusing the resources in the projects with high potential. In this sense, she leaded the merger between XPol and Sygnis AG as a reverse acquisition aiming to be public in the German market.



Araclon Biotech, S.L.

• Spain
• Biotechnology
• 1 - 100 Employee

• Advisor to the board

  • Dec 2010 - Dec 2011

• Director General

  • Jun 2007 - Dec 2010

  During this period, the company moved from being a start-up based in two patents and with a very reduced team, to a biotech company with a staff of 30 people, two Alzheimer (AD) diagnostic kits CE marked and with two clinical trials on going, and a therapy to treat AD entering in clinical trials.



Viuda de Federico Giner

• CFO/Board member

  • 2006 - 2009



Neuropharma

• Biotechnology Research
• 1 - 100 Employee

• CEO

  • Jan 2004 - Jun 2006

  Neuropharma was a company created from the business development unit of Zeltia during Pilar's mandate. The company was focus in the development of drugs to treat Alzheimer desease, and during Pilar's mandate the company went from an idea based in two patents (no employees or facilities) to a company with 60 people, one lab well equipped lab in Madrid, two compounds in clinical trials, two capital increases well covered by external investors (more than 20M euros collected) and more than 30 patents presented.



Zeltia, S.A.

• Business development Director (VP)

  • Jun 2000 - Jan 2004

• CFO

  • Jan 1999 - Jun 2000

  During this period Zeltia did the biggest capital increase done by a Biotech company in Europe, getting more than 230M euros from the stock exchange market. The capital increase was covered with Spanish, European and USA investors.



Metrologie Iberica

• CFO

  • Apr 1997 - Dec 1998